8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Mar 31, 2026·SEC
Barinthus Biotherapeutics plc(BRNS)Earnings, Financials & Key Ratios
BRNS•NASDAQ
$0.63
Price updated Jul 7, 2026
AboutBarinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.Show more
- Revenue$0-100.0%
- EBITDA-$48M+22.2%
- Net Income-$66M-8.8%
- EPS (Diluted)-1.64-5.8%
- ROE-64.99%-68.7%
BRNS Price & Volume
Barinthus Biotherapeutics plc (BRNS) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Generation Potential
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding exhaustion
Key Thesis Takeaways
- Barinthus Biotherapeutics is currently navigating a high-risk transition to a pure-play clinical-stage biotech, characterized by a complete cessation of revenue and significant quarterly net losses.
- The company's future hinges on the successful validation of its T-cell redirection platform, yet the rapid erosion of its cash position from $142.1 million in 2023Q4 to $65.9 million in 2026Q1 suggests a looming need for dilutive financing.
- Investors should monitor the clinical progress of VTP-300 and VTP-200, as the firm's $309.6 million accumulated deficit highlights the substantial capital intensity required to reach commercial viability.
Verdict Logic
the company's reliance on a diminishing cash balance of $65.9 million against a backdrop of consistent quarterly net losses often exceeding $15 million suggests significant risk of future shareholder dilution.
BRNS Growth Metrics
Barinthus Biotherapeutics plc (BRNS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM21.34%
Return on Capital
10 Years-59.57%
5 Years-30.55%
3 Years-40.76%
Last Year-46.55%
Peers Comparison
Key metrics vs top competitors for Barinthus Biotherapeutics plc (BRNS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.63 | $25.69M | -0.38 | -100% | — | -64.99% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $3.38 | $241.82M | -2.40 | — | — | -30.9% | — | |
| $33.40 | $1.7B | -63.02 | 20% | -4.88% | -4.83% | — | |
| $1.35 | $171.71M | -1.21 | 14.85% | -173.02% | — | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — |
Compare BRNS vs Peers
Barinthus Biotherapeutics plc (BRNS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BRNS SEC Filings & Documents
Barinthus Biotherapeutics plc (BRNS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BRNS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BRNS Frequently Asked Questions
Barinthus Biotherapeutics plc (BRNS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Barinthus Biotherapeutics plc growing?
Barinthus Biotherapeutics plc (BRNS) saw revenue decline by 100.0% over the past year.
Is BRNS profitable?
Barinthus Biotherapeutics plc (BRNS) reported a net loss of $52.3M for fiscal year 2025.
Dividend & Returns
What is BRNS's return on equity?
Barinthus Biotherapeutics plc (BRNS) has a return on equity (ROE) of -65.0%. Negative ROE indicates the company is unprofitable.
What is Barinthus Biotherapeutics plc's free cash flow?
Barinthus Biotherapeutics plc (BRNS) had negative free cash flow of $36.4M in fiscal year 2025, likely due to heavy capital investments.